{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:46:02Z","timestamp":1789688762964,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.breast.2025.104612","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:38:07Z","timestamp":1760535487000},"page":"104612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025\u20132035 (Goal 9)"],"prefix":"10.1016","volume":"84","author":[{"given":"Alexandru","family":"Eniu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runcie C.W.","family":"Chidebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vuylsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Penault-Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Neciosup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Attfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-2249","authenticated-orcid":false,"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2025.104612_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.annonc.2024.12.005","article-title":"ESMO Global consortium study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.breast.2022.07.006","article-title":"Progression-free survival and quality of life in metastatic breast cancer: the patient perspective","volume":"65","author":"Mertz","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2025.104612_bib3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/EDBK_359521","article-title":"Cancer groundshot: building a robust cancer control platform in addition to launching the cancer moonshot","author":"Mutebi","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.breast.2025.104612_bib4","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/cncr.32910","article-title":"Breast cancer treatment: a phased approach to implementation","volume":"126","author":"Mutebi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2025.104612_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: decade report (2005\u20132015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.breast.2025.104612_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab063","article-title":"Projecting the prevalence and costs of Metastatic Breast Cancer from 2015 through 2030","volume":"5","author":"Gogate","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.breast.2025.104612_bib10","article-title":"Treatment sequencing patterns and associated direct medical costs of metastatic breast cancer care in the United States, 2011 to 2021","volume":"5","author":"Chehayeb","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2025.104612_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and projections of the global economic cost of 29 Cancers in 204 Countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib12","article-title":"An arm and a leg: the rising cost of cancer drugs and impact on access","volume":"e1\u2013e12","author":"Leighl","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.breast.2025.104612_bib13","author":"Hofmarcher"},{"key":"10.1016\/j.breast.2025.104612_bib14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10198-016-0832-z","article-title":"Does drug price-regulation affect healthcare expenditures?","volume":"18","author":"Ben-Aharon","year":"2017","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.breast.2025.104612_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241354","article-title":"The cost of cancer \u2013 a comparative analysis of the direct medical costs of cancer and other major chronic diseases in Europe","volume":"15","author":"Schlueter","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2025.104612_bib16","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/S2666-7568(24)00108-9","article-title":"The economic burden of cancer, coronary heart disease, dementia, and stroke in England in 2018, with projection to 2050: an evaluation of two cohort studies","volume":"5","author":"Filipa","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.breast.2025.104612_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s41669-022-00327-5","article-title":"Differences in breast cancer costs by cancer stage and biomarker subtype in New Zealand","volume":"6","author":"Lao","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.breast.2025.104612_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10549-020-05654-x","article-title":"Medical costs associated with metastatic breast cancer in younger, midlife, and older women","volume":"181","author":"Trogdon","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104612_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ejhpharm-2017-001453","article-title":"The economic burden of metastatic breast cancer in Spain","volume":"27","author":"Bbdl","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.breast.2025.104612_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230909","article-title":"Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands","volume":"15","author":"Schneider","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2025.104612_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7057","article-title":"Why is end\u2010of\u2010life inpatient cost high among cancer patients? A prospective cohort study","volume":"13","author":"Balasubramanian","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.breast.2025.104612_bib22","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1002\/cncr.33077","article-title":"Productivity costs associated with metastatic breast cancer in younger, midlife, and older women","volume":"126","author":"Trogdon","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2025.104612_bib24","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(23)01701-4","article-title":"Women, power, and cancer: a Lancet commission","volume":"402","author":"Ophira","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2025.104612_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2025.104612_bib27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/MNM.0000000000000752","article-title":"Improving women's health in low-income and middle-income countries. Part II","volume":"38","author":"Mariani","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.breast.2025.104612_bib28","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/cncr.32872","article-title":"Can pathology diagnostic services for cancer be stratified and serve global health?","volume":"126","author":"Anglade","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2025.104612_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/ajcp\/aqw143","article-title":"An essential pathology package for Low- and middle-income countries","author":"Fleming","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2025.104612_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-020-05752-y","article-title":"Breast cancer pathology services in Sub-Saharan Africa: a survey within population-based cancer registries","volume":"20","author":"Ziegenhorn","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.breast.2025.104612_bib31","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/MNM.0000000000000752","article-title":"Improving women's health in low-income and middle-income countries. Part II","volume":"38","author":"Mariani","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.breast.2025.104612_bib32","doi-asserted-by":"crossref","first-page":"e1203","DOI":"10.1016\/S2214-109X(20)30261-8","article-title":"Breast cancer survival and survival gap apportionment in Sub-Saharan Africa (ABC-DO): a prospective cohort study","volume":"8","author":"Valerie","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.breast.2025.104612_bib33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2025.104612_bib34","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib35","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/OP.21.00466","article-title":"Financial burden of drugs prescribed for cancer-associated symptoms","volume":"18","author":"Gupta","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.breast.2025.104612_bib37","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(21)00463-0","article-title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","volume":"22","author":"Adam","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1470-2045(25)00071-3","article-title":"Revolutionising cancer treatment access in low-income and middle-income countries: a sustainable approach","volume":"26","author":"Amy","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/27550834241256450","article-title":"Global pharma departure from Nigeria: a threat to public health","volume":"8","author":"Aluh","year":"2024","journal-title":"J Med Access"},{"key":"10.1016\/j.breast.2025.104612_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41571-022-00700-7","article-title":"Barriers in access to oncology drugs \u2014 a global crisis","volume":"20","author":"Barrios","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib41","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1016\/S2214-109X(25)00138-X","article-title":"Substandard anticancer medications in clinical care settings and private pharmacies in Sub-Saharan Africa: a systematic pharmaceutical investigation","volume":"13","author":"J","year":"2025","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.breast.2025.104612_bib42","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jnci\/djae307","article-title":"Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer","volume":"117","author":"Reibel","year":"2025","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.breast.2025.104612_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/OP.23.00545","article-title":"Drug shortages in oncology: ASCO clinical guidance for alternative treatments","volume":"20","author":"Se","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.breast.2025.104612_bib44","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2023.1650","article-title":"Barriers to optimal management of cancer pain in Sub-Saharan Africa: a scoping review","volume":"17","author":"Magboh","year":"2023","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.breast.2025.104612_bib45","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2401331121","article-title":"Sex bias in pain management decisions","volume":"121","author":"Guzikevits","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.breast.2025.104612_bib46","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/cncr.32899","article-title":"Situational analysis of breast health care systems: why context matters","volume":"126","author":"Duggan","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2025.104612_bib48","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/annonc\/mdw213","article-title":"ESMO European Consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe","volume":"27","author":"Cherny","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib49","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1093\/annonc\/mdx521","article-title":"ESMO international consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100362","article-title":"Prioritising systemic cancer therapies applying esmo's tools and other resources to assist in improving cancer care globally: the Kazakh experience","volume":"7","author":"Latino","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2025.104612_bib51","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S1470-2045(24)00505-9","article-title":"Use of the ESMO-magnitude of clinical benefit scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis","volume":"25","author":"Panos","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib52","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib53","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib54","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamaoncol.2022.0159","article-title":"Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer","volume":"8","author":"Malinowski","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad067","article-title":"Medicaid expansion is associated with treatment receipt, timeliness, and outcomes among young adults with breast cancer","volume":"7","author":"Ji","year":"2023","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.breast.2025.104612_bib56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21556660.2020.1857103","article-title":"Review of cyclin-dependent kinase 4\/6 inhibitors in the treatment of advanced or metastatic breast cancer","volume":"10","author":"Husinka","year":"2021","journal-title":"J Drug Assess"},{"key":"10.1016\/j.breast.2025.104612_bib58","article-title":"Socioeconomic inequalities in adherence to clinical practice guidelines and breast cancer survival: a multicentre population-based study in Spain","author":"Petrova","year":"2024","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.breast.2025.104612_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthplace.2024.103301","article-title":"The unfairness of place: a cultural history of the UK's \u2018postcode lottery\u2019","volume":"90","author":"Redhead","year":"2024","journal-title":"Health Place"},{"key":"10.1016\/j.breast.2025.104612_bib60","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.canep.2010.01.008","article-title":"Geographic variation in breast cancer care in Switzerland","volume":"34","author":"Ess","year":"2010","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.breast.2025.104612_bib61","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/S1470-2045(21)00351-X","article-title":"Radiotherapy resources in Africa: an international atomic energy agency update and analysis of projected needs","volume":"22","author":"Elmore","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib62","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: a lancet oncology commission","volume":"25","author":"May","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clon.2016.11.011","article-title":"Analysis of global radiotherapy needs and costs by geographic region and income level","volume":"29","author":"Zubizarreta","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semradonc.2016.11.011","article-title":"Challenges and prospects for providing radiation oncology services in Africa","volume":"27","author":"Balogun","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2022.09.001","article-title":"Radiotherapy prioritization in 143 national cancer control plans: correlation with radiotherapy machine availability, geography and income level","volume":"176","author":"Wilson","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib67","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.breast.2020.12.010","article-title":"Why is appropriate healthcare inaccessible for many European breast cancer patients? \u2013 the EBCC 12 manifesto","volume":"55","author":"Cardoso","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.breast.2025.104612_bib68","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clon.2020.12.008","article-title":"The financial impact on reimbursement of moderately hypofractionated postoperative radiation therapy for breast cancer: an international consortium report","volume":"33","author":"Marta","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib70","first-page":"1","article-title":"Disparities in breast, lung, and cervical cancer trials worldwide","author":"Ramaswami","year":"2018","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib71","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2023.7314","article-title":"Analysis and optimization of equitable US cancer clinical trial center access by travel time","volume":"10","author":"Lee","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib72","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae085","article-title":"Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023","volume":"8","author":"Guadamuz","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.breast.2025.104612_bib73","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.2022.40.16_suppl.1014","article-title":"Increasing black patient participation in metastatic breast cancer clinical trials: the BECOME (black experience of clinical trials and opportunities for meaningful engagement) project","volume":"40","author":"Stephanie","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104612_bib74","article-title":"Clinical trial discussion and participation in a breast cancer cohort by race and ethnicity","volume":"8","author":"Chen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2025.104612_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.22515","article-title":"Racial and ethnic inequities in US oncology clinical trial participation from 2017 to 2022","volume":"6","author":"Pittell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2025.104612_bib77","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.55388","article-title":"Financial toxicity among patients with breast cancer worldwide","volume":"6","author":"Ehsan","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2025.104612_bib79","first-page":"137","article-title":"Financial toxicity among people with metastatic cancer: findings from the cancer experience registry","volume":"32","author":"Mollica","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.breast.2025.104612_bib80","doi-asserted-by":"crossref","first-page":"11930","DOI":"10.1002\/cam4.5885","article-title":"Multidimensional financial hardship among uninsured and insured young adult patients with metastatic breast cancer","volume":"12","author":"Wheeler","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.breast.2025.104612_bib81","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/OP.24.00339","article-title":"Defining and measuring financial toxicity in Low- and middle-income countries","volume":"21","author":"Raptis","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.breast.2025.104612_bib82","doi-asserted-by":"crossref","first-page":"PS9","DOI":"10.1158\/1538-7445.SABCS20-PS9-16","article-title":"Abstract PS9-16: Long-term personal, social and financial impact of advanced breast cancer: results from the invisible woman 2.0, a Pan-European patient and carer survey","volume":"81","author":"Decise","year":"2021","journal-title":"Cancer Res"},{"issue":"12_Supplement","key":"10.1016\/j.breast.2025.104612_bib85","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-PS10-06","article-title":"Access to innovative medicines for advanced breast cancer as a catalyst for health systems strengthening in Low- and middle-income countries","volume":"31","author":"Cardoso","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625006290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625006290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:32:12Z","timestamp":1773315132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625006290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":71,"alternative-id":["S0960977625006290"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104612","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025\u20132035 (Goal 9)","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104612"}}